EP3007678A1 - Pharmaceutical composition comprising amorphous sunitinib - Google Patents
Pharmaceutical composition comprising amorphous sunitinibInfo
- Publication number
- EP3007678A1 EP3007678A1 EP13728425.3A EP13728425A EP3007678A1 EP 3007678 A1 EP3007678 A1 EP 3007678A1 EP 13728425 A EP13728425 A EP 13728425A EP 3007678 A1 EP3007678 A1 EP 3007678A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sunitinib
- pharmaceutically acceptable
- composition according
- polymer
- solid composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 title claims abstract description 37
- 239000002147 L01XE04 - Sunitinib Substances 0.000 title claims abstract description 35
- 229960001796 sunitinib Drugs 0.000 title claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 229920001577 copolymer Polymers 0.000 claims abstract description 37
- 239000002131 composite material Substances 0.000 claims abstract description 31
- 239000007787 solid Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 18
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims abstract description 14
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000007887 hard shell capsule Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- -1 glidants Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229920001429 chelating resin Polymers 0.000 description 19
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 238000000634 powder X-ray diffraction Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 4
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940116298 l- malic acid Drugs 0.000 description 3
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 3
- 239000003495 polar organic solvent Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960002812 sunitinib malate Drugs 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- GIST gastrointestinal stromal tumors
- MRCC metastatic renal cell carcinoma
- pancreatic pancreatic
- sunitinib L-malate which is the active ingredient in the medicinal product sold under the brand name SUTENT® by Pfizer.
- Sunitinib L-malate exhibits polymorphism.
- WO03016305 discloses form I and II of sunitinib L-malate, processes for their preparation and compositions comprising these forms. Form I is the most stable form and is present in the marketed capsules.
- Other polymorphic forms of sunitinib L-malate are disclosed in WO2009067686, WO2009104021, WO2010010454, WO2010055082, WO2010076805 and WO2011092664.
- Sunitinib L-malate is considered to be a low permeability compound. Furthermore, its solubility rapidly decreases at pH greater than 6.8. For this reason, sunitinib is classified as a low solubility compound according to the biopharmaceutical classification. To improve its dissolution behavior and bioavailability, it would be desirable to have sunitinib L-malate in amorphous form, since the solubility of amorphous forms is higher compared to the solubility of crystalline forms.
- WO2009156837 discloses amorphous sunitinib L-malate. Amorphous compositions comprising sunitinib and its acid addition salt are disclosed in WO2009100929 and
- WO2010039798 Paragraph [0045] of WO2010039798 reads: "Attempts to prepare amorphous sunitinib malate or an amorphous composition of sunitinib base and L-malic acid without excipients (see Ex. 7 and 28) or even with an excipient (see Ex. 8-27 and 29) were unsuccessful, i.e., the sunitinib base-L-malic acid composition was not amorphous. In the obtained product, peaks of crystalline composition of sunitinib base and L-malic acid are evident.” In our laboratory, these findings were confirmed.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an amorphous solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
- the invention provides a process for preparing said pharmaceutical composition comprising mixing or granulating said solid composite with one or more excipients and filling into hard shell capsules.
- Said pharmaceutical composition may be used as a medicament, particularly in the treatment of a tyrosine kinase-related disorder.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising an amorphous solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
- sunitinib, or a pharmaceutically acceptable salt thereof, and the (co)polymer are preferably intimately associated, meaning that there is attractive interaction between the active pharmaceutical ingredient and the (co)polymer.
- the weight ratio of sunitinib, or a pharmaceutically acceptable salt thereof, to (co)polymer in the solid composite typically ranges from 1: 1 to 1:6, preferably from 1: 1.5 to 1:3.
- a carboxylic acid group bearing (co)polymer, a hydroxyl group bearing (co)polymer, as well as a mixture of a carboxylic acid bearing (co)polymer and a hydroxyl group bearing (co)polymer can be used.
- a carboxylic acid group bearing (co)polymer, a hydroxyl group bearing (co)polymer, as well as a mixture of a carboxylic acid bearing (co)polymer and a hydroxyl group bearing (co)polymer can be used.
- a carboxylic acid group bearing (co)polymer, a hydroxyl group bearing (co)polymer, as well as a mixture of a carboxylic acid bearing (co)polymer and a hydroxyl group bearing (co)polymer can be used.
- (co)polymer bearing both carboxylic acid and hydroxyl groups can be used.
- a carboxylic acid group bearing (co)polymer or a hydroxyl group bearing (co)polymer is used.
- the (co)polymer is preferably a carboxylic acid group bearing copolymer, preferably selected from the group consisting of acrylate (co)polymers, celluloses and phthalate
- the carboxylic acid group bearing copolymer is an acrylate copolymer of methacrylic acid and divinylbenzene, and is known under the international non- proprietary name (INN) polyacrilex resin.
- the carboxylic acid groups are in the H+ form.
- Typical examples of commercially available resins include Amberlite IRP 64 and Indion 214.
- the (co)polymer of the solid composite may also be a hydroxyl group bearing
- polyvinyl alcohol preferably polyvinyl alcohol.
- PVA polyvinyl alcohol
- Kollicoat IR polyvinyl alcohol- polyethylene glycol graft copolymer
- the (co)polymer of the solid composite may also bear both carboxylic acid and hydroxyl groups.
- Typical examples of such commercially available resins include
- HPMCP hypromellose phthalate
- the solid composite of the present invention containing sunitinib, or a pharmaceutically acceptable salt thereof, is present in a stabilized amorphous form, which means that during stability studies no conversion into any crystalline form was observed.
- the solid composite in accordance with the present invention advantageously is in the form of a free-flowing powder, with excellent handling properties.
- the solid composite is very suitable to be used for the preparation of pharmaceutical compositions.
- compositions of the present invention comprise the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
- excipients to be used in accordance with the present invention are well- known to and are those excipients which are conventionally used by the person skilled in the art. Depending on the dosage form chosen for the pharmaceutical composition, the person skilled in the art will be able to select suitable pharmaceutically acceptable excipients.
- the pharmaceutically acceptable excipients are chosen from one or more binders, diluents, disintegrants, glidants or lubricants.
- one or more excipients from the group of stabilizers, surface active agents or pH-adjusting agents may be added.
- compositions of the present invention display dissolution behavior typical for immediate-release formulations.
- compositions of the present invention the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer remains in the amorphous form.
- the present invention further provides a process to prepare a solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, comprising combining the (co)polymer with sunitinib, or a pharmaceutically acceptable salt thereof, in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s), using equipment and methods well-known in the art.
- the solvent or solvent mixture is a polar solvent or a mixture of water and a polar organic solvent.
- sunitinib, or a pharmaceutically acceptable salt thereof is dissolved in a polar solvent or a mixture of water and a polar organic solvent and the solution is added to a suspension of the copolymer in water.
- Preferred polar organic solvents are alcohols, particularly ethanol or methanol, ethers, particularly tetrahydrofuran, ketones, particularly acetone and acetonitrile.
- a mixture of an alcohol and water is used.
- the present invention still further provides a process to prepare pharmaceutical compositions comprising a solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, and one or more pharmaceutically acceptable excipients.
- the process comprises mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients and filling into hard shell capsules, using equipment and methods well-known to the skilled artisan.
- the hard shell capsules may be filled with just the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, in the absence of any excipient.
- the pharmaceutical composition in accordance with the present invention may be used as a medicament.
- the pharmaceutical composition typically may be used in the treatment of a tyrosine kinase-related disorder, preferably for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (MRCC) and pancreatic neuroendocrine tumors (pNET).
- GIST gastrointestinal stromal tumors
- MRCC metastatic renal cell carcinoma
- pNET pancreatic neuroendocrine tumors
- the present invention is illustrated by the following Examples.
- XRPD data showed that the isolated solid composite was fully amorphous.
- XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C /90% RH and 3 months at 40°C/75 RH showed that the composite was still fully amorphous.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising an amorphous solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of a tyrosine kinase-related disorder.
Description
PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS
SUNITINIB BACKGROUND OF THE PRESENT INVENTION
Sunitinib, chemically (Z)-N-[2-(diethylamino)ethyl]-5-(5-fluoro-2-oxo-2,3-dihydro- lH-indol-3-ylidenemethyl)-2,4-dimethyl-lH-pyrrole-3-carboxamide of formula (I),
is a pharmaceutically active compound used for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (MRCC) and pancreatic
neuroendocrine tumors (pNET). The compound was discovered by Sugen and is disclosed in WO0160814. The compound may form acid addition salts, for instance sunitinib L-malate, which is the active ingredient in the medicinal product sold under the brand name SUTENT® by Pfizer. Sunitinib L-malate exhibits polymorphism. WO03016305 discloses form I and II of sunitinib L-malate, processes for their preparation and compositions comprising these forms. Form I is the most stable form and is present in the marketed capsules. Other polymorphic forms of sunitinib L-malate are disclosed in WO2009067686, WO2009104021, WO2010010454, WO2010055082, WO2010076805 and WO2011092664.
Sunitinib L-malate is considered to be a low permeability compound. Furthermore, its solubility rapidly decreases at pH greater than 6.8. For this reason, sunitinib is classified as a low solubility compound according to the biopharmaceutical classification. To improve its
dissolution behavior and bioavailability, it would be desirable to have sunitinib L-malate in amorphous form, since the solubility of amorphous forms is higher compared to the solubility of crystalline forms.
WO2009156837 discloses amorphous sunitinib L-malate. Amorphous compositions comprising sunitinib and its acid addition salt are disclosed in WO2009100929 and
WO2010039798. Paragraph [0045] of WO2010039798 reads: "Attempts to prepare amorphous sunitinib malate or an amorphous composition of sunitinib base and L-malic acid without excipients (see Ex. 7 and 28) or even with an excipient (see Ex. 8-27 and 29) were unsuccessful, i.e., the sunitinib base-L-malic acid composition was not amorphous. In the obtained product, peaks of crystalline composition of sunitinib base and L-malic acid are evident." In our laboratory, these findings were confirmed. Attempts were made to prepare stable amorphous sunitinib L-malate preparations, amongst others by repeating Example 2 of WO2009156837. However, all these attempts failed, since sunitinib L-malate crystallizes very easily.
Thus in view of the prior art cited above, there is still a need for stable, amorphous compositions comprising sunitinib, or a pharmaceutically acceptable salt thereof, having improved solubility.
BRIEF DESCRIPTION OF THE PRESENT INVENTION
The present invention provides a pharmaceutical composition comprising an amorphous solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
It also provides a process for preparing said solid composite by combining sunitinib, or a pharmaceutically acceptable salt thereof, with a carboxylic acid and/or hydroxyl group
bearing (co)polymer in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s).
Additionally, the invention provides a process for preparing said pharmaceutical composition comprising mixing or granulating said solid composite with one or more excipients and filling into hard shell capsules.
Said pharmaceutical composition may be used as a medicament, particularly in the treatment of a tyrosine kinase-related disorder.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
The present invention relates to a pharmaceutical composition comprising an amorphous solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
In the solid composite, sunitinib, or a pharmaceutically acceptable salt thereof, and the (co)polymer are preferably intimately associated, meaning that there is attractive interaction between the active pharmaceutical ingredient and the (co)polymer. The weight ratio of sunitinib, or a pharmaceutically acceptable salt thereof, to (co)polymer in the solid composite typically ranges from 1: 1 to 1:6, preferably from 1: 1.5 to 1:3.
In accordance with the present invention a carboxylic acid group bearing (co)polymer, a hydroxyl group bearing (co)polymer, as well as a mixture of a carboxylic acid bearing (co)polymer and a hydroxyl group bearing (co)polymer can be used. Moreover, a
(co)polymer bearing both carboxylic acid and hydroxyl groups can be used. Preferably, either a carboxylic acid group bearing (co)polymer or a hydroxyl group bearing (co)polymer is used.
The (co)polymer is preferably a carboxylic acid group bearing copolymer, preferably selected from the group consisting of acrylate (co)polymers, celluloses and phthalate
(co)polymers. More preferably the carboxylic acid group bearing copolymer is an acrylate copolymer of methacrylic acid and divinylbenzene, and is known under the international non- proprietary name (INN) polyacrilex resin. Typically, the carboxylic acid groups are in the H+ form. Typical examples of commercially available resins include Amberlite IRP 64 and Indion 214.
The (co)polymer of the solid composite may also be a hydroxyl group bearing
(co)polymer, preferably a polyvinyl alcohol. Typical examples of commercially available polyvinyl alcohols are polyvinyl alcohol (PVA) and Kollicoat IR (polyvinyl alcohol- polyethylene glycol graft copolymer).
The (co)polymer of the solid composite may also bear both carboxylic acid and hydroxyl groups. Typical examples of such commercially available resins include
hypromellose phthalate (HPMCP).
The solid composite of the present invention containing sunitinib, or a pharmaceutically acceptable salt thereof, is present in a stabilized amorphous form, which means that during stability studies no conversion into any crystalline form was observed. The solid composite in accordance with the present invention advantageously is in the form of a free-flowing powder, with excellent handling properties. The solid composite is very suitable to be used for the preparation of pharmaceutical compositions.
The pharmaceutical compositions of the present invention comprise the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients. The excipients to be used in accordance with the present invention are well- known to and are those excipients which are conventionally used by the person skilled in the
art. Depending on the dosage form chosen for the pharmaceutical composition, the person skilled in the art will be able to select suitable pharmaceutically acceptable excipients.
Preferably, the pharmaceutically acceptable excipients are chosen from one or more binders, diluents, disintegrants, glidants or lubricants. In addition, one or more excipients from the group of stabilizers, surface active agents or pH-adjusting agents may be added.
The pharmaceutical compositions of the present invention display dissolution behavior typical for immediate-release formulations. During preparation and storage of the
pharmaceutical compositions of the present invention, the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer remains in the amorphous form.
The present invention further provides a process to prepare a solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, comprising combining the (co)polymer with sunitinib, or a pharmaceutically acceptable salt thereof, in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s), using equipment and methods well-known in the art.
Preferably, the solvent or solvent mixture is a polar solvent or a mixture of water and a polar organic solvent. In an advantageous variant of the process of the present invention, sunitinib, or a pharmaceutically acceptable salt thereof, is dissolved in a polar solvent or a mixture of water and a polar organic solvent and the solution is added to a suspension of the copolymer in water. Preferred polar organic solvents are alcohols, particularly ethanol or methanol, ethers, particularly tetrahydrofuran, ketones, particularly acetone and acetonitrile. Preferably, a mixture of an alcohol and water is used.
The present invention still further provides a process to prepare pharmaceutical compositions comprising a solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, and one or more
pharmaceutically acceptable excipients. The process comprises mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients and filling into hard shell capsules, using equipment and methods well-known to the skilled artisan. Alternatively, the hard shell capsules may be filled with just the solid composite of sunitinib, or a pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer, in the absence of any excipient.
The pharmaceutical composition in accordance with the present invention may be used as a medicament. The pharmaceutical composition typically may be used in the treatment of a tyrosine kinase-related disorder, preferably for the treatment of gastrointestinal stromal tumors (GIST), metastatic renal cell carcinoma (MRCC) and pancreatic neuroendocrine tumors (pNET).
The present invention is illustrated by the following Examples.
EXAMPLES
Example 1, sunitinib L-malate:Amberlite IRP 64 (weight ratio 1:4)
To 8 g of Amberlite IRP 64, 32 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 2 g of Sunitinib L-malate was dissolved in 50 ml of a mixture of water and ethanol (1: 1) while heating. The clear solution was added to the Amberlite mixture and the resulting suspension was stirred for 3 hours at 60°C. The suspension was concentrated in vacuo. Due to foaming, 20 ml of ethanol was added and the concentration in vacuo was continued. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous. XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C/90 RH and 3 months at 40°C Π5% RH showed that the composite was still fully amorphous.
Example 2, sunitinib free base: Amberlite IRP 64 (weight ratio 1:4)
To 8 g of Amberlite IRP 64, 32 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 2 g of Sunitinib free base was dissolved in 70 ml of ethanol while heating. The clear solution was added to the Amberlite mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
Isolated solid: 8.6 g
XRPD data showed that the isolated solid composite was fully amorphous. XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C /90% RH and 3 months at 40°C/75 RH showed that the composite was still fully amorphous.
Example 3, sunitinib L-malate: Amberlite IRP 64 (weight ratio 1:3)
To 1 g of Amberlite IRP 64, 4 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 0.33 g of Sunitinib L-malate was dissolved in 8 ml of a mixture of water and ethanol (1: 1) while heating. The clear solution was added to the
Amberlite mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous.
Example 4, sunitinib besylate: Amberlite IRP 64 (weight ratio 1:4)
To 1 g of Amberlite IRP 64, 4 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 0.25 g of Sunitinib besylate was dissolved in 8 ml of a mixture of water and ethanol (1: 1) while heating. The clear solution was added to the Amberlite
mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous. XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C/90 RH showed that the composite was still fully amorphous.
Example 5, sunitinib succinate: Amberlite IRP 64 (weight ratio 1:4)
To 1 g of Amberlite IRP 64, 4 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 0.25 g of Sunitinib succinate was dissolved in 8 ml of a mixture of water and ethanol (1: 1) while heating. The clear solution was added to the
Amberlite mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous. XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C/90 RH showed that the composition was still fully amorphous.
Example 6, sunitinib hydrochloride: Amberlite IRP 64 (weight ratio 1:4)
To 0.64 g of Amberlite IRP 64, 2.6 ml of water was added and the resulting mixture was stirred for 60 minutes at 60°C. 0.16 g of Sunitinib hydrochloride was dissolved in 5.1 ml of a mixture of water and ethanol (1: 1) while heating. The clear solution was added to the Amberlite mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous. XRPD analysis performed 4 weeks after subjecting the powder in open dish to 55°C/90 RH showed that the composition was still fully amorphous.
Example 7, sunitinib L-malate:HPMCP (weight ratio 1:4)
To 1 g of HPMCP, 5 ml of water was added and the resulting suspension was stirred for 60 minutes at 60°C. 0.25 g of Sunitinib L-malate was dissolved in 6.5 ml of a mixture water and ethanol (1: 1). The clear solution was added to the HPMCP mixture and the resulting suspension was stirred for 2 hours at 60°C. The suspension was concentrated in vacuo. The residue was dried over night at 40°C under vacuum.
XRPD data showed that the isolated solid composite was fully amorphous.
Claims
1. A pharmaceutical composition comprising a solid composite of sunitinib, or a
pharmaceutically acceptable salt thereof, and a carboxylic acid and/or hydroxyl group bearing (co)polymer and optionally one or more pharmaceutically acceptable excipients.
2. The composition according to claim 1, wherein the carboxylic acid group bearing
(co)polymer is selected from the group consisting of acrylate (co)polymers, celluloses, and phthalate (co)polymers.
3. The composition according to claim 2, wherein the acrylate copolymer is a polacrilex resin.
4. The composition according to claim 1, wherein the hydroxyl group bearing
(co)polymer is a polyvinyl alcohol.
5. The composition according to any one of claims 1 to 4, wherein the weight ratio of sunitinib, or a pharmaceutically acceptable salt thereof, to (co)polymer ranges from 1: 1 to 1:6.
6. The composition according to any one of claims 1 to 5 comprising the L-malic acid salt of sunitinib.
7. The composition according to any one of claims 1 to 6, wherein sunitinib [in the solid composite] is in an amorphous form.
8. The composition according to any one of claims 1 to 7, wherein the pharmaceutically acceptable excipients are one or more binders, diluents, disintegrants, glidants, lubricants, stabilizers, surface active agents or pH-adjusting agents.
9. A process for preparing the composition according to any one of claims 1 to 7
comprising combining sunitinib, or a pharmaceutically acceptable salt thereof, with a
carboxylic acid and/or hydroxyl group bearing (co)polymer in a suitable solvent or solvent mixture, followed by evaporation of the solvent(s).
10. The process according to claim 9, wherein the solvent is a polar solvent selected from the group consisting of alcohols, ethers, ketones, acetonitrile and water or a mixture thereof.
11. The process according to claim 9 or 10 further comprising mixing or granulating the solid composite with one or more pharmaceutically acceptable excipients and filling into hard shell capsules.
12. The composition according to any one of claims 1 to 8, for use as a medicament.
13. The composition according to claim 12 for use in the treatment of a tyrosine kinase- related disorder.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/062422 WO2014198342A1 (en) | 2013-06-14 | 2013-06-14 | Pharmaceutical composition comprising amorphous sunitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3007678A1 true EP3007678A1 (en) | 2016-04-20 |
Family
ID=48613654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13728425.3A Withdrawn EP3007678A1 (en) | 2013-06-14 | 2013-06-14 | Pharmaceutical composition comprising amorphous sunitinib |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP3007678A1 (en) |
| WO (1) | WO2014198342A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| KR102308227B1 (en) * | 2018-10-31 | 2021-10-05 | 주식회사 삼양홀딩스 | Oral tablet composition containing sunitinib |
| WO2020091439A1 (en) * | 2018-10-31 | 2020-05-07 | 주식회사 삼양바이오팜 | Oral formulation comprising sunitinib and preparation method therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2713112A1 (en) * | 2008-02-13 | 2009-08-20 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
-
2013
- 2013-06-14 EP EP13728425.3A patent/EP3007678A1/en not_active Withdrawn
- 2013-06-14 WO PCT/EP2013/062422 patent/WO2014198342A1/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO2014198342A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014198342A1 (en) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775464B2 (en) | Delayed release oral dosage composition containing amorphous CDDO-ME | |
| US12233069B2 (en) | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor | |
| BR112020014487A2 (en) | pharmaceutical compositions for the treatment of cystic fibrosis | |
| JP6355645B2 (en) | Solid dispersion with improved solubility, containing tetrazole derivative as active ingredient | |
| US12502384B2 (en) | Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor | |
| WO2017108605A1 (en) | Pharmaceutical composition comprising amorphous dasatinib | |
| KR102223105B1 (en) | Film formulation containing tadalafil free base comprising polyethylene glycol based polymer and/or vinylpyrrolidone base polymer as dispersing agents | |
| US9655885B2 (en) | Amorphous mirabegron and processes for crystal forms of mirabegron | |
| WO2016038532A1 (en) | Amorphous treprostinil diethanolamine | |
| US10660963B2 (en) | Pharmaceutical composition containing tacrolimus and preparation methods thereof | |
| EP3007678A1 (en) | Pharmaceutical composition comprising amorphous sunitinib | |
| KR101282847B1 (en) | Solid dispersion containing cilostazol and pharmaceutical composition comprising the same | |
| CN114096239B (en) | Compressed macitentan compositions, methods and uses thereof | |
| Maggi et al. | II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: Co-milling | |
| CN105126111A (en) | Preparation for improving bioavailability of sorafenib | |
| KR102228135B1 (en) | Pharmaceutical compositions in the form of solid formulation comprising resveratrol and methods for solubilizing resveratrol | |
| KR102697985B1 (en) | Pharmaceutical composition and method for preparing same | |
| WO2016169534A1 (en) | Solid forms of amorphous empagliflozin | |
| US11116769B2 (en) | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer | |
| US12036214B2 (en) | Solid dispersion comprising an anticancer compound for improved solubility and efficacy | |
| WO2014095818A1 (en) | Formulation comprising amorphous agomelatine | |
| US10752618B2 (en) | Process for the preparation of pure and stable crystalline Raltegravir potassium form 3 | |
| EP3073996A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| EP3082772A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| KR20190001714A (en) | Method of manufacturing Choline Alfoscerate solid particles, Choline Alfoscerate solid formulations using thereof and Choline Alfoscerate particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160114 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20170918 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180130 |